May 09, 2017 - Names on the move ahead of the open.
May 09, 2017 - Allergan plc's (AGN) first-quarter 2017 earnings came in at $3.35 per share, beating the Zacks Consensus Estimate of $3.32 by 0.9%.
May 09, 2017 - Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.
May 09, 2017 - Allergan???s first-quarter earnings of $3.35 per share were above our consensus estimate of $3.32 per share.
May 08, 2017 - With so many companies reporting earnings, Tracey wades through all the noise to bring you the best charts.
Apr 25, 2017 - Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Apr 25, 2017 - Without price increases or deals to boost earnings, the pharmaceuticals sector faces a weak earnings season.
Apr 24, 2017 - Allergan, Express Scripts, and Vertex stocks look attractive in a generally overpriced market.
Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis